12-22-06

Elease type a plus sign (+) inside this box  $\rightarrow$ Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/533,144 **Application Number** T& TRAD Filing Date April 24, 2006 TRANSMITTAL MASUDA, ESTEBAN First Named Inventor **FORM** Group Art Unit 1654 Not yet assigned (to be used for all correspondence after initial filing) **Examiner Name RIGL-023** Attorney Docket Number Total Number of Pages in This Submission ENCLOSURES (check all that apply) Fee Transmittal Form After Allowance Communication **Assignment Papers** to Group (for an Application) Fee Attached Appeal Communication to Board Drawing(s) of Appeals and Interferences Amendment / Reply Licensing-related Papers After Final Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Certification Regarding Sequence Affidavits/declaration(s) Listing Proprietary Information Extension of Time Request Petition to Convert to a Status Letter Provisional Application **Express Abandonment Request** Power of Attorney, Revocation Other Enclosure(s) (please Information Disclosure Statement Change of Correspondence identify below): Address Certified Copy of Priority **Copy of Notification to Comply Terminal Disclaimer Documents** Paper copy Sequence Listing (4 pgs) Request for Refund Response to Missing Parts/ **CRF Sequence Listing** Incomplete Application Return postcard CD, Number of CD(s Response to Missing Parts under 37 CFR 1.52 or 1.53 Remarks SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Signing Attorney/Agent JAMES S. KEDDIE, PH.D., 48,920 (Reg. No.) CEVIC, FIELD & FRANCIS, LLP

EXPRESS MAIL LABEL NO. EV 687 640 743 US

Signature

Date

December 20, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerca, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. BOX 1450 Alexandria, Virginia 22313-1450 www.unpto.gov

U.S. APPLICATION NUMBER NO.

FIRST NAMED APPLICANT

ATTY. DOCKET NO.

10/533,144

Esteban Masuda

RIGL-023

24353

**BOZICEVIC, FIELD & FRANCIS LLP** 1900 UNIVERSITY AVENUE

SUITE 200 EAST PALO ALTO, CA 94303 DEC 2 0 2006

PCT/US03/27370 I.A. FILING DATE PRIORITY DATE 08/30/2003 08/30/2002

INTERNATIONAL APPLICATION NO.

**CONFIRMATION NO. 5373** 

**371 FORMALITIES LETTER** 

\*OC000000021300239\*

Date Mailed: 11/20/2006

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821-1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

See the attachment.

## Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

NUV 2 8 2006

Dozicevic, Field, & Francis



For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web. https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at http://www.uspto.gov/ebc.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

**DONNA S GREENE** 

Telephone: (703) 308-9140 EXT 222

## PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY, DOCKET NO.
10/533,144	PCT/US03/27370	RIGL-023

FORM PCT/DO/EO/922 (371 Formalities Notice)